BiotechTube
Home/Rigel Pharmaceuticals/Raymond J. Furey
RJ

Raymond J. Furey

Executive Vice President, General Counsel and Corporate Secretary

Rigel Pharmaceuticals

Therapeutic Areas

HematologyOncologyImmunology

Rigel Pharmaceuticals Pipeline

DrugIndicationPhase
TAVALISSE (fostamatinib)Chronic Immune Thrombocytopenia (ITP)Marketed
REZLIDHIA (olutasidenib)Relapsed/Refractory AML with IDH1 mutationMarketed
GAVRETO (pralsetinib)RET+ Non-Small Cell Lung CancerMarketed
IRAK1/4 InhibitorLower-Risk Myelodysplastic Syndrome (LR-MDS)Phase 1b
RIPK1 InhibitorImmunological DiseasesPreclinical/Discovery

Leadership Team at Rigel Pharmaceuticals

RR
Raul R. Rodriguez
President and Chief Executive Officer
DS
Dean Schorno
Executive Vice President and Chief Financial Officer
DA
David A. Santos
Executive Vice President and Chief Commercial Officer
LR
Lisa Rojkjaer
Executive Vice President and Chief Medical Officer
JL
Joseph Lasaga
Executive Vice President and Chief Business Officer
JP
Julie Patel
Senior Vice President, Human Resources
KA
Kamil Ali-Jackson
Board Director
MW
Mark W. Frohlich
Board Director
View full Rigel Pharmaceuticals profile